1-3 of 3
Xiaohua Xin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors

Michael L. Maitland, Jasgit C. Sachdev, Manish R. Sharma, Victor Moreno, Valentina Boni, Shivaani Kummar, Erica Stringer-Reasor, Nehal Lakhani, Allison R. Moreau, Dawei Xuan, Ray Li, Eric L. Powell, Amy Jackson-Fisher, Michelle Bowers, Shilpa Alekar, Xiaohua Xin, Anthony W. Tolcher, Emiliano Calvo
Journal: Clinical Cancer Research
Clin Cancer Res (2021) 27 (16): 4511–4520.
https://doi.org/10.1158/1078-0432.CCR-20-3757
Published: 15 August 2021
View article titled, First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors
Open the PDF for First-in-Human Study of PF-06647020 (Cofetuzumab Pelidotin), an Antibody–Drug Conjugate Targeting Protein Tyrosine Kinase 7, in Advanced Solid Tumors in another window
Includes: Supplementary data
Journal Articles

CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice

Xiaohua Xin, Tinya J. Abrams, Paul W. Hollenbach, Katherine G. Rendahl, Yan Tang, Yoko A. Oei, Millicent G. Embry, Debbie E. Swinarski, Evelyn N. Garrett, Nancy K. Pryer, Suzanne Trudel, Bahija Jallal, Dirk B. Mendel, Carla C. Heise
Journal: Clinical Cancer Research
Clin Cancer Res (2006) 12 (16): 4908–4915.
https://doi.org/10.1158/1078-0432.CCR-06-0957
Published: 16 August 2006
View article titled, CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice
Open the PDF for CHIR-258 Is Efficacious in A Newly Developed Fibroblast Growth Factor Receptor 3–Expressing Orthotopic Multiple Myeloma Model in Mice in another window
Journal Articles

In Vivo Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: Determination of a Pharmacokinetic/Pharmacodynamic Relationship

Dirk B. Mendel, A. Douglas Laird, Xiaohua Xin, Sharianne G. Louie, James G. Christensen, Guangmin Li, Randall E. Schreck, Tinya J. Abrams, Theresa J. Ngai, Leslie B. Lee, Lesley J. Murray, Jeremy Carver, Emily Chan, Katherine G. Moss, Joshua Ö. Haznedar, Juthamas Sukbuntherng, Robert A. Blake, Li Sun, Cho Tang, Todd Miller, Sheri Shirazian, Gerald McMahon, Julie M. Cherrington
Journal: Clinical Cancer Research
Clin Cancer Res (2003) 9 (1): 327–337.
Published: 01 January 2003
View article titled, <em>In Vivo</em> Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: <subtitle>Determination of a Pharmacokinetic/Pharmacodynamic Relationship</subtitle>
Open the PDF for <em>In Vivo</em> Antitumor Activity of SU11248, a Novel Tyrosine Kinase Inhibitor Targeting Vascular Endothelial Growth Factor and Platelet-derived Growth Factor Receptors: <subtitle>Determination of a Pharmacokinetic/Pharmacodynamic Relationship</subtitle> in another window